

type of report	Current report
number	71/2013
company	PHARMENA

Information on the progress in clinical trials over innovative anti-atherosclerosis medicinal product 1-MNA

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and the communication on obtaining authorisation for phase II clinical trials of anti-atherosclerosis medicinal product 1-MNA (published in current report no. 70/2013 of 8th October 2013), the Management Board of PHARMENA S.A. informs on the progress in the choice of research centres taking part in clinical trials of 1-MNA medicinal product.

Until 9th October 2013, fourteen research centres, which fulfil the criteria of patients' inclusion, were qualified for carrying out clinical trials. Next stage will comprise of trainings for people responsible for conducting the trials in the selected research centres, so that they become acquainted with the program and timetable of the scheduled clinical trials. Simultaneously, the search for other research centres for the clinical trials is continued. Having concluded the process of verification, the final number of research centres taking part in the clinical trials will be established.

The aim of the phase II clinical trial over the 1-MNA anti-atherosclerosis medicinal product will consist in establishing the effective dose of the medicinal product and confirming the lack of side effects in humans in the tested doses. Planned time scope for the trial is 12 months from the date of obtaining permission from Health Canada market regulator. The supervisory institution will be Montreal Heart Institute, and participation of ca. 15 clinics in the trial is planned.

Montreal Heart Institute is a leading research centre in Canada, specialising in cardiology, and one of the largest institutes of this type in the world. It is a world renown Institute, that has introduced many innovatory solutions nationally and world-wide. For more information see www.icm-mhi.org.

Phase II clinical trial ("Proof of Concept") is planned to be financed from funds raised in issue of series D shares. Subsequent current reports issued by the Company will inform on progress of research and trials of the 1-MNA innovative anti-atherosclerotic medicinal product.

This information is made public due to the fact that conducting phase II clinical trial is necessary for commercialisation of 1-MNA anti-atherosclerotic medicinal product project, while potential revenues on the medicinal product commercialisation may have very significant impact on financial results and market valuation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (2.2)".

Representatives of the company:

- Konrad Palka – President of the Board
- Marzena Wiczorkowska – Vice President of the Board